UK markets open in 5 hours 43 minutes
NIKKEI 225
38,669.25 -277.68 (-0.71%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,425.50 -0.40 (-0.02%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,200.71 -688.30 (-1.23%)
GC Biopharma Corp. (006280.KS)
KSE - KSE Delayed price. Currency in KRW
Add to watchlist
As of 09:56AM KST. Market open.
| Previous close | 113,900.00 |
| Open | 113,900.00 |
| Bid | 115,000.00 x 0 |
| Ask | 115,300.00 x 0 |
| Day's range | 113,900.00 - 115,600.00 |
| 52-week range | 93,000.00 - 131,100.00 |
| Volume | |
| Avg. volume | 20,136 |
| Market cap | 1.314T |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | 1,500.00 (1.32%) |
| Ex-dividend date | 27 Dec 2023 |
| 1y target est | 144,333.00 |
PR NewswireGC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A.
- PR Newswire
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval.
PR NewswireGC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
GC Cell, a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug 'Immuncell-LC' at the AACR Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.
© 2024 Yahoo. All rights reserved.